{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:17Z","timestamp":1793908637024,"version":"4.8.0"},"reference-count":34,"publisher":"Massachusetts Medical Society","issue":"9","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,3,4]]},"DOI":"10.1056\/nejmoa2008290","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T17:02:00Z","timestamp":1614790920000},"page":"818-828","source":"Crossref","is-referenced-by-count":469,"title":["Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome"],"prefix":"10.1056","volume":"384","author":[{"given":"Florence","family":"Wong","sequence":"first","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Chris","family":"Pappas","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Curry","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond A.","family":"Rubin","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Porayko","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan A.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mumtaz","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lim","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Simonetto","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Sharma","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Todd","family":"Frederick","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Escalante","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Jamil","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) \u2014 both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.","volume":"56","author":"Salerno F","year":"2007","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318.17389705","journal-title":"Gut"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/apt.14052","article-title":"Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.","volume":"45","author":"Sanyal AJ","year":"2017","unstructured":"Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther 2017;45:1390-1402.28370090","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-018-0022-7","article-title":"Hepatorenal syndrome.","volume":"4","author":"Gin\u00e8s P","year":"2018","unstructured":"Gin\u00e8s P, Sol\u00e0 E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018;4:23-23.30213943","journal-title":"Nat Rev Dis Primers"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/17474124.2017.1356223","article-title":"Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis.","volume":"11","author":"Zheng J-N","year":"2017","unstructured":"Zheng J-N, Han Y-J, Zou T-T, et al. Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2017;11:1009-1018.28708431","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JEP.S146034","article-title":"In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2.","volume":"10","author":"Jamil K","year":"2017","unstructured":"Jamil K, Pappas SC, Devarakonda KR. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2. J Exp Pharmacol 2017;10:1-7.29302194","journal-title":"J Exp Pharmacol"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00365520310008728","article-title":"Effect of terlipressin on blood volume distribution in patients with cirrhosis.","volume":"39","author":"Kiszka-Kanowitz M","year":"2004","unstructured":"Kiszka-Kanowitz M, Henriksen JH, Hansen EF, M\u00f8ller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 2004;39:486-492.15180188","journal-title":"Scand J Gastroenterol"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/CCM.0b013e3182120842","article-title":"The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function.","volume":"39","author":"Mukhtar A","year":"2011","unstructured":"Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit Care Med 2011;39:1329-1334.21336108","journal-title":"Crit Care Med"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal AJ","year":"2008","unstructured":"Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368.18471513","journal-title":"Gastroenterology"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.","volume":"134","author":"Mart\u00edn-Llah\u00ed M","year":"2008","unstructured":"Mart\u00edn-Llah\u00ed M, P\u00e9pin M-N, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359.18471512","journal-title":"Gastroenterology"},{"issue":"7","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1.","volume":"150","author":"Boyer TD","year":"2016","unstructured":"Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 2016;150(7):1579-1589.e2.26896734","journal-title":"Gastroenterology"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jgh.14009","article-title":"Terlipressin: current and emerging indications in chronic liver disease.","volume":"33","author":"Papaluca T","year":"2018","unstructured":"Papaluca T, Gow P. Terlipressin: current and emerging indications in chronic liver disease. J Gastroenterol Hepatol 2018;33:591-598.28981166","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis.","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-460.29653741","journal-title":"J Hepatol"},{"key":"e_1_3_5_14_2","unstructured":"Food and Drug Administration. Special protocol assessment: guidance for industry. April 2018 (https:\/\/www.fda.gov\/media\/97618\/download)."},{"key":"e_1_3_5_15_2","first-page":"67","article-title":"Verified hepatorenal syndrome reversal as a robust multi-component primary end point: the CONFIRM study trial design.","volume":"11","author":"Jamil K","year":"2019","unstructured":"Jamil K, Pappas SC, Wong F, Sanyal AJ. Verified hepatorenal syndrome reversal as a robust multi-component primary end point: the CONFIRM study trial design. J Clin Trials 2019;11:67-73.","journal-title":"J Clin Trials"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.","volume":"62","author":"Angeli P","year":"2015","unstructured":"Angeli P, Gin\u00e8s P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62:968-974.25638527","journal-title":"J Hepatol"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2215\/CJN.03610417","article-title":"Prognosis of patients with cirrhosis and AKI who initiate RRT.","volume":"13","author":"Allegretti AS","year":"2018","unstructured":"Allegretti AS, Vela Parada X, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol 2018;13:16-25.29122911","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1055\/s-0038-1661372","article-title":"Renal function in cirrhosis: a critical review of available tools.","volume":"38","author":"Piano S","year":"2018","unstructured":"Piano S, Brocca A, Angeli P. Renal function in cirrhosis: a critical review of available tools. Semin Liver Dis 2018;38:230-241.30041275","journal-title":"Semin Liver Dis"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.cgh.2018.04.020","article-title":"When should we stop treatment with terlipressin and albumin for patients with hepatorenal syndrome?","volume":"16","author":"Reiberger T","year":"2018","unstructured":"Reiberger T. When should we stop treatment with terlipressin and albumin for patients with hepatorenal syndrome? Clin Gastroenterol Hepatol 2018;16:1710-1711.29684461","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ki.2014.338","article-title":"Renal dysfunction in cirrhosis is not just a vasomotor nephropathy.","volume":"87","author":"Adebayo D","year":"2015","unstructured":"Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int 2015;87:509-515.25296092","journal-title":"Kidney Int"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/SHK.0000000000000052","article-title":"A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury.","volume":"41","author":"Gomez H","year":"2014","unstructured":"Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014;41:3-11.24346647","journal-title":"Shock"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2013.12.032","article-title":"Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.","volume":"60","author":"Rodr\u00edguez E","year":"2014","unstructured":"Rodr\u00edguez E, Elia C, Sol\u00e0 E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol 2014;60:955-961.24447876","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cgh.2016.07.016","article-title":"Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome.","volume":"15","author":"Wong F","year":"2017","unstructured":"Wong F, Pappas SC, Boyer TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome. Clin Gastroenterol Hepatol 2017;15(2):266-272.e1.27464593","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.","volume":"2","author":"Facciorusso A","year":"2017","unstructured":"Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2017;2:94-102.28403995","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_3_5_25_2","first-page":"CD005162","article-title":"Terlipressin for hepatorenal syndrome.","volume":"9","author":"Gluud LL","year":"2012","unstructured":"Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012;9:CD005162-CD005162.22972083","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/0253-7613.106436","article-title":"Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis.","volume":"45","author":"Hiremath SB","year":"2013","unstructured":"Hiremath SB, Srinivas LD. Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis. Indian J Pharmacol 2013;45:54-60.23543867","journal-title":"Indian J Pharmacol"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"e0431","DOI":"10.1097\/MD.0000000000010431","article-title":"Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.","volume":"97","author":"Wang H","year":"2018","unstructured":"Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e0431-e0431.29668606","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cgh.2017.05.041","article-title":"New developments in hepatorenal syndrome.","volume":"16","author":"Mindikoglu AL","year":"2018","unstructured":"Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. Clin Gastroenterol Hepatol 2018;16(2):162-177.e1.28602971","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_5_29_2","unstructured":"Runyon BA. Practice guideline \u2014 management of adult patients with ascites due to cirrhosis: Update 2012. Alexandria VA: American Association for the Study of Liver Diseases 2012."},{"key":"e_1_3_5_30_2","first-page":"CD011532","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome.","volume":"9","author":"Israelsen M","year":"2017","unstructured":"Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev 2017;9:CD011532-CD011532.28953318","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.","volume":"62","author":"Cavallin M","year":"2015","unstructured":"Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 2015;62:567-574.25644760","journal-title":"Hepatology"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/j.1440-1746.2009.05873.x","article-title":"Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.","volume":"24","author":"Narahara Y","year":"2009","unstructured":"Narahara Y, Kanazawa H, Taki Y, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1791-1797.19686420","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/MEG.0b013e32833a4822","article-title":"Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis.","volume":"22","author":"Krag A","year":"2010","unstructured":"Krag A, Bendtsen F, Mortensen C, Henriksen JH, M\u00f8ller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol 2010;22:1085-1092.20453655","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00535-011-0485-8","article-title":"The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.","volume":"47","author":"Narahara Y","year":"2012","unstructured":"Narahara Y, Kanazawa H, Sakamoto C, et al. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol 2012;47:313-320.22038555","journal-title":"J Gastroenterol"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S1499-3872(12)60204-5","article-title":"Terlipressin improves pulmonary pressures in cirrhotic patients with pulmonary hypertension and variceal bleeding or hepatorenal syndrome.","volume":"11","author":"Kalambokis GN","year":"2012","unstructured":"Kalambokis GN, Pappas K, Tsianos EV. Terlipressin improves pulmonary pressures in cirrhotic patients with pulmonary hypertension and variceal bleeding or hepatorenal syndrome. Hepatobiliary Pancreat Dis Int 2012;11:434-437.22893473","journal-title":"Hepatobiliary Pancreat Dis Int"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2008290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:36:08Z","timestamp":1711485368000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2008290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3,4]]}},"alternative-id":["10.1056\/NEJMoa2008290"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2008290","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739666493.793585270","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.739666493.793585333","asserted-by":"object"}]},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}